Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein Jκ

Journal of Virology

Volumn 69, Issue 5, 1995, Pages 3108-3116

  Robertson, Erle S ^a   Grossman, Steven ^a   Johannsen, Eric ^a   Miller, Cheryl ^a   Lin, Jeffrey ^a   Tomkinson, Blake ^a,b   Kieff, Elliott ^a  

^a HARVARD UNIVERSITY   (United States)

^b Supragen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; NUCLEAR PROTEIN; VIRUS DNA; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BINDING SITE; DNA SEQUENCE; EPSTEIN BARR VIRUS; LYMPHOCYTE TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION; VIRUS TRANSCRIPTION;

EID: 0028903431     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.69.5.3108-3116.1995     Document Type: Article

References (66)

1. Abbot, S. D., M. Rowe, K. Cadwallader, A. Ricksten, J. Gordon, K. Wang, L. Rymo, and A. B. Rickinson. 1990. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J. Virol. 64:2126-2134.
2. Alfieri, C., M. Birkenbach, and E. Kieff. 1991. Early events in Epstein-Barr virus infection of human lymphocytes. Virology 181:595-608.
3. Allday, M., D. Crawford, and B. Griffin. 1989. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J. Gen. Virol. 70:1755-1764.
4. 1-arrested cells. J. Virol. 68:3491-3498.
5. Baer, R., A. T. Bankier, M. D. Biggin, P. L. Deininger, P. J. Farrell, T. J. Gibson, G. Hatfull, G. S. Hudson, S. C. Satchwell, C. Séguin, P. S. Tuffnell, and B. G. Barrell. 1984. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (London) 310:207-211.
6. Boos, H., R. Berger, C. Kulik-Roos, T. Iftner, and N. Mueller-Lantxsch, 1987. Enhancement of Epstein-Barr virus (EBV) latent membrane protein (LMP) expression by serum, TPA, or n-butyrate in latently infected Raji cells. Virology 159:161-165.
7. Calender, A., M. Billaud, J. P. Aubry, J. Banchereau, M. Vuillaume, and G. Lenoir. 1987. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc. Natl. Acad. Sci. USA 84:8060-8064.
8. Cohen, J. I., and E. Kieff. 1991. An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J. Virol. 65:5880-5885.
9. Cohen, J. I., F. Wang, and E. Kieff. 1991. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J. Virol. 65:2545-2554.
10. Cohen, J. I., F. Wang, J. Mannick, and E. Kieff. 1989. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. USA 86:9558-9562.
11. Dou, S., X. Zeng, P. Cortes, H. Erdjument-Bromage, P. Tempst, T. Honjo, and L. D. Vales. 1994. The recombination signal sequence-binding protein RBP-2N functions as a transcriptional repressor. Mol. Cell. Biol. 14:3310-3319.
12. Ellisen, L. W., J. Bird, D. C. West, A. L. Soreng, T. C. Reynolds, S. D. Smith, and J. Sklar. 1991. Tan-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66:649-661.
13. Fahraeus, R., A. Jansson, A. Kicksten, A. Sjoblom, and L. Rymo. 1990. Epstein-Barr virus encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc. Natl. Acad. Sci. USA 87:7390-7394.
14. Fahraeus, R., A. Jansson, A. Sjoblom, T. Nilsson, G. Klein, and L. Rymo. 1993. Cell phenotype-dependent control of Epstein-Barr virus latent membrane protein 1 gene regulatory sequences. Virology 195:71-80.
15. Fortini, M. E., and S. Artavanis-Tsakonas. 1994. The suppressor of Hairless protein participates in Notch receptor signaling. Cell 79:273-282.
16. Furukawa, T., S. Maruyama, M. Kawaichi, and T. Honjo. 1992. The Drosophila homolog of the immunoglobulin recombination signal-binding protein regulates peripheral nervous system development. Cell 69:1191-1197.
17. Galson, D. L., J. O. Hensold, T. R. Bishop, M. Schalling, A. D. D'Andrea, C. Jones, P. E. Auron, and D. E. Housman. 1993. Mouse β-globin DNA-binding protein B1 is identical to a proto-oncogene, the transcription factor Spi-1/ PU.1, and is restricted in expression to hematopoietic cells and the testis. Mol. Cell. Biol. 13:2929-2941.
18. Grossman, S. R., E. Johannsen, X. Tong, R. Yalamanchili, and E. Kieff. 1994. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the Jκ recombination signal binding protein. Proc. Natl. Acad. Sci. USA 91:7568-7572.
19. Hamaguchi, Y., Y. Yamamoto, H. Iwanari, S. Maruyama, T. Furukawa, N. Matsunami, and T. Honjo. 1992. Biochemical and immunological characterization of the DNA binding protein (RBP-Jκ) to mouse Jκ recombination signal sequence. J. Biochem. 112:314-320.
20. Hammerschmidt, W., and B. Sugden. 1989. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature (London) 340:393-397.
21. Henkel, T., P. D. Ling, S. D. Hayward, and M. G. Peterson. 1994. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein Jκ. Science 265:92-95.
22. Izumi, K. M., K. M. Kaye, and E. D. Kieff. 1994. Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation. J. Virol. 68:4369-4376.
23. Jin, X. W., and S. H. Speck. 1992. Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter. J. Virol. 66:2846-2852.
24. Johannsen, E., E. Koh, G. Mosialos, X. Tong, E. Kieff, and S. R. Grossman. 1995. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by Jκ and PU.1. J. Virol. 69:253-262.
25. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90:9150-9154.
26. Kieff, E. D. 1995. Epstein-Barr virus. In B. N. Fields, P. Howley, D. Knipe, et al. (ed.), Virology, 3rd ed., in press. Raven Press, New York.
27. Klemsz, M. J., S. R. McKercher, A. Celada, C. Van Beveren, and R. A. Maki. 1990. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 61:113-124.
28. Knutson, J. C. 1990. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J. Virol. 64: 2530-2536.
29. Ling, P. D., D. R. Rawlins, and S. D. Hayward. 1993. The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc. Natl. Acad. Sci. USA 90:9237-9241.
30. Longnecker, R., C. L. Miller, X.-Q. Miao, A. Marchini, and E. Kieff. 1992. The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential. J. Virol. 66:6461-6469.
31. Longnecker, R., C. L. Miller, X.-Q. Miao, B. Tomkinson, and E. Kieff. 1993. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. J. Virol. 67:2006-2013
32. Longnecker, R., C. L. Miller, B. Tomkinson, X.-Q. Miao, and E. Kieff. 1993. Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J. Virol. 67:5068-5074.
33. Luckow, B., and G. Shutz. 1987. CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Res. 15:5490.
34. Mannick, J. B., J. L. Cohen, M. Birkenbach, A. Marchini, and E. Kieff. 1991. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs (EBNA-LP) is important in B-lymphocyte transformation. J. Virol. 65:6826-6837.
35. Maunders, M. J, L. Petti, and M. Rowe. 1994. Precipitation of Epstein-Barr virus protein EBNA 2 by an EBNA 3C-specific monoclonal antibody. J. Gen. Virol. 75:769-778.
36. Meitinger, C., L. J. Strobl, G. Marschall, G. W. Bornkamm, and U. Zimber-Strobl. 1994. Crucial sequences within the Epstein-Barr virus TP1 promoter for EBNA2-mediated transactivation and interaction of EBNA2 with its responsive element. J. Virol. 68:7497-7506.
37. Mitchell, P. J., and R. Tijan. 1989. Transcriptional regulation in mammalian cells by sequence specific DNA binding proteins. Science 245:371-378.
38. 2+/calmodulin-dependent protein kinase, CaM kinase-Gr, expressed after transformation of primary human B lymphocytes by Epstein-Barr virus (EBV) is induced by the EBV oncogene LMP1. J. Virol. 68:1697-1705.
39. Petti, L., C. Sample, and E. Kieff. 1990. Subnuclear localization and phosphorylation of Epstein-Barr virus latent infection nuclear proteins. Virology 176:563-574.
40. Petti, L., J. Sample, F. Wang, and E. Kieff. 1988. A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J. Virol. 62:1330-1338.
41. Rickinson, A. B., and E. D. Kieff. 1995. Epstein-Barr virus. In B. N. Fields, P. Howley, D. Knipe, et al., (ed.), Virology, 3rd ed., in press. Raven Press, New York.
42. Robertson, E., and E. Kieff. 1995. Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs. J. Virol. 69:983-993.
43. Robertson, E. S., B. Tomkinson, and E. Kieff. 1994. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARFO transforms B lymphocytes in vitro. J. Virol. 68:1449-1458.
44. Rooney, C., M. Brimmell, M. Buschle, G. Allan, P, J. Farrell, and J. I. Kolman. 1992. Host cell and EBNA 2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J. Virol. 66:496-504.
45. Sample, J., L. Young, B. Martin, T. Chatman, E. Kieff, A. Rickinson, and E. Kieff. 1990. Epstein-Barr virus types 1 and 2 differ in their EBNA 3A, EBNA 3B, and EBNA 3C genes. J. Virol. 64:4084-4092.
46. Schweisguth, F., and J. W. Posakony. 1992. Suppressor of Hairless, the Drosophila homolog of the mouse recombination signal-binding protein gene, controls sensory organ cell fates. Cell 69:1199-1212.
47. Sugden, B., K. Marsh, and J. Yates. 1985. A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol. Cell. Biol. 5:410-413.
48. Sugden, B., and N. Warren. 1989. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNAl, a viral protein required for viral DNA replication during latent infection. J. Virol. 63:2644-2649.
49. Swaminathan, S., B. Tomkinson, and E. Kieff. 1991. Recombinant Epstein-Barr virus with small RNA (EBERs) genes deleted transforms lymphocytes and replicates in vitro. Proc. Natl. Acad. Sci. USA 88:1546-1550.
50. Tomkinson, B., and E. Kieff. 1992. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J. Virol. 66:2893-2903.
51. Tomkinson, B., E. S. Robertson, and E, Kieff. 1993. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67:2014-2025.
52. Tong, X., F. Wang, C. J. Thut, and E. Kieff. 1995. The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFlIB, TAF40, and RPA70 but not with TATA-binding protein. J. Virol. 69:585-589.
53. Tong, X., R. Yalamanchili, S. Harada, and E. Kieff. 1994. The EBNA-2 arginine-glycine domain is critical but not essential for B-lymphocyte growth transformation; the rest of region 3 lacks essential interactive domains. J. Virol. 68:6188-6197.
54. Tsang, S.-F., F. Wang, K. M. Izumi, and E. Kieff. 1991. Delineation of the as-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression. J. Virol. 65:6765-6771.
55. Tun, T., Y. Hamaguchi, N. Matsunami, T. Furukawa, T. Honjo, and M. Kawaichi. 1994. Recognition sequence of a highly conserved DNA binding protein RBP-JK. Nucleic Acids Res. 22:965-971.
56. Vinson, C. R., P. B. Sigler, and S. L. McKnight. 1989. Scissors-grip model for DNA recognition by a family of leucine zipper proteins. Science 246:911-916.
57. Wang, D., D. Liebowitz, and E. Kieff. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840.
58. Wang, D., D. Liebowitz, F. Wang, C. Gregory, A. Rickinson, R. Larson, T. Springer, and E. Kieff. 1988. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J. Virol. 62:4173-4184.
59. Wang, F., C. Gregory, M. Rowe, A. Rickinson, D. Wang, M. Birkenbach, H. Kikutani, T. Kishimoto, and E. Kieff. 1987. Epstein-Barr virus nuclear protein 2 specifically induces expression of the B cell antigen, CD23. Proc. Natl. Acad. Sci. USA 84:3452-3456.
60. Wang, F., C. Gregory, C. Sample, M. Rowe, D. Liebowitz, R. Murray, A. Rickinson, and E. Kieff. 1990. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64:2309-2318.
61. Wang, F., S. Tsang, M. G. Kurilla, J. I. Cohen, and E. Kieff. 1990. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMPl. J. Virol. 64:3407-3416.
62. Yalamanchili, R., X. Tong, S. R. Grossman, E. Johannsen, G. Mosialos, and E. Kieff. 1994. Genetic and biochemical evidence that EBNA 2 interaction with a 63 Kd cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. Virology 204:634-641.
63. Yates, J. L., N. Warren, D. Reisman, and B. Sugden. 1984. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc. Natl. Acad. Sci. USA 81:3806-3810.
64. Young, L., C. Alfieri, K. Hennesy, H. Evans, C. O'Hara, K. C. Anderson, J. Ritz, R. S. Shapiro, A. B. Rickinson, E. Kieff, and J. I. Cohen. 1989. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lympholiferative disease. N. Engl. J. Med. 321:1080-1085.
65. Zimber-Strobl, U., E. Kremmer, F. Grasser, G. Marschall, G. Laux, and G. W. Bornkamm. 1993. The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA 2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J. 12:167-175.
66. Zimber-Strobl, U., L. Strobl, C. Meitinger, R. Hinrichs, T. Sakai, T. Furukawa, T. Honjo, and G. Bornkamm. 1994. Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-Jκ, the homologue of Drosophila suppressor of Hairless. EMBO. J. 13:4973-4982.